Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Nateglinide is a meglitinide used for the treatment of type 2 diabetes mellitus. Individual studies demonstrated the association of CYP2C9, SLCO1B1, and MTNR1B variants with the safety and efficacy of nateglinide. The current study aimed to develop a pharmacogenomic algorithm to optimize nateglinide therapy.
Methods: Multiple linear regression (MLR) and classification and regression tree (CART) were used to develop a pharmacogenomic algorithm for nateglinide dosing based on the published nateglinide pharmacokinetic data on the area under the curve data (AUC) and C (n = 143). CYP2C9 metabolizer phenotype, SLCO1B1, MTNR1B genotypes, and CYP2C9 inhibitor usage were used as the input variables. The results and associations were further confirmed by meta-analysis and in silico studies.
Results: The MLR models of AUC and C explain 87.4% and 59% variability in nateglinide pharmacokinetics. The Bland and Altman analysis of the nateglinide dose predicted by these two MLR models showed a bias of ± 26.28 mg/meal. The CART algorithm was proposed based on these findings. This model is further justified by the meta-analysis showing increased AUCs in CYP2C9 intermediate metabolizers and SLCOB1 TC and CC genotypes compared to the wild genotypes. The increased AUC in SLCO1B1 mutants is due to decreased binding affinity of nateglinide to the mutant affecting the influx of nateglinide into hepatocytes. MTNR1B rs10830963 G-allele-mediated poor response to nateglinide is attributed to increased transcriptional factor binding causing decreased insulin secretion.
Conclusion: CYP2C9, SLCO1B1, and MTNR1B genotyping help in optimizing nateglinide therapy based on this algorithm and ensuring safety and efficacy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s43440-022-00400-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identifying meaningful drug response biomarkers from public pharmacogenomic datasets with biologically informed interpretable neural networks.
Comput Biol Chem
September 2025
Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macao Special Administrative Region of China. Electronic address:
With the advancements of next-generation sequencing, publicly available pharmacogenomic datasets from cancer cell lines provide a handle for developing predictive models of drug responses and identifying associated biomarkers. However, many currently available predictive models are often just used as black boxes, lacking meaningful biological interpretations. In this study, we made use of open-source drug response data from cancer cell lines, in conjunction with KEGG pathway information, to develop sparse neural networks, K-net, enabling the prediction of drug response in EGFR signaling pathways and the identification of key biomarkers.
View Article and Find Full Text PDFExtracting Clinical Guideline Information Using Two Large Language Models: Evaluation Study.
J Med Internet Res
September 2025
Artificial Intelligence Center, China Medical University Hospital, 2, Yude Road, Taichung, 404327, Taiwan, 886 4-22052121.
Background: The effective implementation of personalized pharmacogenomics (PGx) requires the integration of released clinical guidelines into decision support systems to facilitate clinical applications. Large language models (LLMs) can be valuable tools for automating information extraction and updates.
Objective: This study aimed to assess the effectiveness of repeated cross-comparisons and an agreement-threshold strategy in 2 advanced LLMs as supportive tools for updating information.
GENETIC ASPECTS OF WARFARIN DOSING ALGORITHMS IN CARDIAC SURGERY PATIENTS WHO HAVE UNDERGONE HEART SURGERY: SYSTEMATIC REVIEW.
Georgian Med News
June 2025
4Department of Cardiac Surgery and Heart Transplantation, Joint-Stock Company "National Scientific Center of Surgery named after A.N. Syzganov", Almaty, Kazakhstan.
Objective: To evaluate the clinical outcome, safety, and application of personalized therapy using pharmacogenetic warfarin dosing algorithms in cardiac surgery patients systemically.
Methods: This systematic review focused on 17 published studies between January 2015 to March 2025 regarding warfarin dosing algorithms incorporating CYP2C9 and VKORC1 polymorphisms in patients who underwent cardiac surgery. The primary outcomes were TTR, BER, and INR stability.
Artificial Intelligence and Multi-Omics in Pharmacogenomics: A New Era of Precision Medicine.
Mayo Clin Proc Digit Health
September 2025
PGxAI Inc., Palo Alto, CA.
Pharmacogenomics is entering a transformative phase as high-throughput "omics" techniques become increasingly integrated with state-of-the-art artificial intelligence (AI) methods. Although early successes in single-gene pharmacogenetics reported clear clinical benefits, many drug response phenotypes are governed by intricate networks of genomic variants, epigenetic modifications, and metabolic pathways. Multi-omics approaches address this complexity by capturing genomic, transcriptomic, proteomic, and metabolomic data layers, offering a comprehensive view of patient-specific biology.
View Article and Find Full Text PDFQuantum Computing in Drug Discovery Techniques, Challenges, and Emerging Opportunities.
Curr Drug Discov Technol
August 2025
Department of Pharmaceutics, Jayawantrao Sawant College of Pharmacy and Research, Savitribai Phule Pune University, Pune, 411028, India.
Introduction: Quantum computing represents a transformative advancement in computational science, with applications in drug discovery, molecular interaction simulation, drug-target binding optimization, and the analysis of complex biological data at unprecedented speeds and accuracy. Quantum computing emerges as a powerful tool to accelerate the development of new therapeutics, drug design, and the simulation of complex chemical interactions, including personalized medicine strategies. The objective of this study is to explore the potential of quantum computing in drug discovery and development, highlighting its ability to reduce time and costs while accelerating the identification of promising drug candidates.
View Article and Find Full Text PDF